End-of-life CareNCT01428206
Liverpool Care Pathway for the Dying at Residential Care Homes
A study testing Liverpool care pathway in people with End-of-life Care, run by Umeå University at 1 site in Sweden.
Trial summary
Liverpool Care Pathway for the dying patient (LCP) was developed to transfer the care practice from the hospice setting to the hospital setting in UK. LCP is a pathway with standardized registration method to monitor the care and its results. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- End-of-life Care
- What is being tested?
- Liverpool care pathway
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 260 participants
- Where
- 1 siteSweden
- Study dates
- Jun 2009to Dec 2012
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- nursing homes in Skellefteå municipality, Sweden
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
About this study
Liverpool Care Pathway for the dying patient (LCP) was developed to transfer the care practice from the hospice setting to the hospital setting in UK. LCP is a pathway with standardized registration method to monitor the care and its results. The primary aim is to study the effects of LCP on dying patients symptom burden and communication with close relatives and health care professionals.
Read the detailed description
All residential care homes in Skellefteå municipality are included in the study and randomized either to control or intervention group. During the baseline period the care is provided as usual. During the intervention period the LCP is used for patients for whom the dying phase is diagnosed in the intervention group. Usual care is performed for the control group. After death of a patient a close relative fill in a questionnaire.
- Conditions
- End-of-life Care
- Being tested
- Liverpool care pathway
- Keywords
- palliative care, nursing homes, Liverpool care pathway
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Liverpool care pathwayOther
Also called end-of-life care, palliative care
Liverpool care pathway is started tha last day in life for elderly at nursing homes
| Study group | Role | What they receive |
|---|---|---|
| Liverpool care pathway | Other | Liverpool care pathway for dying at nursing homes Receives: Other: Liverpool care pathway |
| control | No intervention | Usual care is performed for the control group |
What is being measured
The primary outcome is the main question the study is designed to answer.
quality of care
changes between the groups about values of symptom scores on the Edmonton assessment scale (ESAS) and the views of informal carers-evaluation of services (VOICES)assessed by close relative
Measured: one month to six months after the relatives death
Secondary outcomes (2)
place of death
changes between the groups
Measured: the time of death
drug consumption
Measured: the last three days before death
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Sep 2011 (estimated)
- Study startJun 2009
- Primary completionDec 2012
- Study completionDec 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for End-of-life CareStudies of the same condition, open and under way.
- More trials run by Umeå UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 260 participants (actual)
Sponsor and investigators
- Lead sponsor
- Umeå University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Margareta Brännström, Umeå University
- Investigators
- Margareta Brännström, PhD, Principal investigator, Department of nursing, Umeå University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01428206
- Sponsor's protocol ID
- LCP001
- Status last verified
- Jun 2013
- First submitted
- 23 Aug 2011
- Last updated
- 14 Jun 2013
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jun 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Liverpool Care Pathway for the Dying at Residential Care Homes
- ClinicalTrials.gov ID
- NCT01428206
- Acronym / sponsor ID
- LCP001
- Conditions
- End-of-life Care
- Keywords
- palliative care, nursing homes, Liverpool care pathway
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 260 participants (actual)
- Lead sponsor
- Umeå UniversityUniversity, hospital or other
- Study start
- Jun 2009
- Primary completion
- Dec 2012 (actual)
- Study completion
- Dec 2012 (actual)
- First posted
- 2 Sep 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Liverpool Care Pathway for the dying patient (LCP) was developed to transfer the care practice from the hospice setting to the hospital setting in UK. LCP is a pathway with standardized registration method to monitor the care and its results. The primary aim is to study the effects of LCP on dying patients symptom burden and communication with close relatives and health care professionals.
Detailed description
All residential care homes in Skellefteå municipality are included in the study and randomized either to control or intervention group. During the baseline period the care is provided as usual. During the intervention period the LCP is used for patients for whom the dying phase is diagnosed in the intervention group. Usual care is performed for the control group. After death of a patient a close relative fill in a questionnaire.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Liverpool care pathway | Other | Other: Liverpool care pathwayLiverpool care pathway for dying at nursing homes |
| control | No intervention | –Usual care is performed for the control group |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- nursing homes in Skellefteå municipality, Sweden
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Liverpool care pathwayAlso: end-of-life care, palliative careLiverpool care pathway is started tha last day in life for elderly at nursing homes | Other | Liverpool care pathway |
Primary outcome
quality of care
Time frame: one month to six months after the relatives death
changes between the groups about values of symptom scores on the Edmonton assessment scale (ESAS) and the views of informal carers-evaluation of services (VOICES)assessed by close relative
2 secondary outcomes
place of death
Time frame: the time of death
drug consumption
Time frame: the last three days before death
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jun 2013.
Related trials for End-of-life Care
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Not yet recruitingObservational study
IN-TALK: Co-producing a Hospice Intimacy Support Toolkit in England
Communication About Intimacy Needs in Hospice and Palliative Care
RecruitingObservational study
Parastomal Hernia at 1 and 3 Years: Radiological Incidence, Progression, and Impact on Quality of Life
Parastomal Hernia, Colorectal Cancer (Diagnosis)
Not yet recruiting
Inpatient Hospice Transitions Checklist
Dementia
Not yet recruiting
Cycling During Dialysis: A Feasibility and Safety Study
Hemodialysis, Kidney Disease, End-Stage
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Margareta Brännström, PhD principal investigator
Department of nursing, Umeå University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Liverpool care pathway in people with End-of-life Care, run by Umeå University at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Jun 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
quality of care (time frame: one month to six months after the relatives death). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jun 2013.